Профилирование аполипопротеинов как вариант персонифицированного подхода к диагностике и коррекции дислипидемий

Профилирование аполипопротеинов как вариант персонифицированного подхода к диагностике и коррекции дислипидемий

Автор: Качковский Михаил Аркадьевич, Введенская Ирина Петровна, Введенский Василий Юрьевич, Супильников Алексей Александрович, Пономарева Юлия Вячеславовна, Милякова Марина Николаевна

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Клиническая медицина

Статья в выпуске: 4 (46), 2020 года.

Бесплатный доступ

В диагностике, методах профилактики и лечении дислипидемий остается множество нерешенных вопросов, несмотря на логичные концепции имеющихся клинических рекомендаций. Среди таких развитие сердечно-сосудистых заболеваний, при достижении и поддержании целевых значений липидного обмена. Это возможно объяснить необходимостью смены парадигмы существующих подходов. С этих позиций аполипопротеины как белковые составляющие липопротеинов могут значительно точнее охарактеризовать дислипидемический статус пациента, поскольку их структура и состав являются уникальными. На основании аполипопрофилирования возможен выбор персонифицированной стратегии профилактики и лечения дислипидемий. В настоящее время появились новые данные о функциях апобелков, их генетических полиморфизмах, предложены молекулярные препараты для коррекции их содержания и липидного обмена в целом.

Еще

Аполипопротеины, атеросклероз, дислипидемия, персонифицированная медицина, риск сердечно-сосудистых заболеваний

Короткий адрес: https://sciup.org/143172384

IDR: 143172384

Список литературы Профилирование аполипопротеинов как вариант персонифицированного подхода к диагностике и коррекции дислипидемий

  • Serdechno-sosudistye zabolevaniya // Vsemirnaya organizaciya zdravoohraneniya: sajt. - Rezhim dostupa: https://www.who.int/topics/cardiovascular_diseases/ru
  • Sergienko I.V., Ansheles A.A., Kuharchuk V.V. Ateroskleroz i dislipidemii: sovremennye aspekty patogeneza, diagnostiki i lecheniya. - M., 2017. - 140 s.
  • Shal'nova S.A. i dr. Analiz smertnosti ot serdechno-sosudistyh zabolevanij v 12 regionah Rossijskoj Federacii, uchastvuyushchih v issledovanii "Epidemiologiya serdechno-sosudistyh zabolevanij v razlichnyh regionah Rossii" // Rossijskij kardiologicheskij zhurnal. - 2012. - № 5 (97). - S. 6-11.
  • Carroll M.D., Fryer C.D., Nguyen D.T. High Total and Low High-Density Lipoprotein Cholesterol in Adults: United States // National Center for Health Statistics. - 2017. - Vol. Hyattsville. MD, USA.
  • Eckel R.H. et al. AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. A Report of the American College of Cardiology // American Heart Association Task Force on Practice Guidelines. Circulation. - 2013. - Vol. 129. - S76-S99.
  • Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children // JCEM. - 2014. - Vol. 99.-P. 3093-3102.
  • Hood L. Systems biology and medicine: past, present, and future // Med J. - 2013. - Vol. 4. - e0012.
  • Mathur S., Sutton J. Personalized medicine could transform healthcare // Biomed Rep. - 2017. - Vol. 7. -P. 3-5.
  • Van der Westhuyzen D.R., de Beer F.C., Webb N.R. HDL cholesterol transport during inflammation // Curr Opin Lipidol. - 2007. - Vol. 18(2). - P. 147-151.
  • Eklund K.K., Niemi K., Kovanen P.T. Immune functions of serum amyloid A // Crit Rev. Immunol. - 2012. -Vol. 32 (4). - P. 335-348.
  • Davey Smith G., Ebrahim S. Mendelian randomization P. can genetic epidemiology contribute to understanding environmental determinants of disease? // Int J Epidemiol. - 2003. - Vol. 32. - P. 1-22.
  • Lawlor D.A., Harbord R.M., Sterne J.A. et al. Mendelian randomization P. using genes as instruments for making causal inferences in epidemiology // Statist Med. - 2008. - Vol. 27. - P. 1133-1163.
  • Wasan K.M. et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery // Nat Rev. Drug Discov. - 2008. - Vol. 7 (1). - P. 84-99.
  • Phillips J.C., Wrigglers W., Li Z., Schulten К. Predicting the structure of apolipoprotein AI in reconstituted high density lipoprotein disks // Biophys J. - 1997. - Vol. 73. - P. 2337-2346.
  • Huang Y. et al. An abundant dysfunctional apolipoprotein A1 in human atheroma // Nat Med. - 2014. - Vol. 20 (2). - P. 193-203.
  • Yui Y. et al. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-l (apo A-l). A novel function of apo A-l // J Clin Invest. - 1988. - Vol. 82(3). - P. 803-807.
  • Franceschini G. et al. Relation between the HDL apoproteins and A-l isoproteins in subjects with the AI Milano abnormality // Metab Clin Exp. - 1981. - Vol. 30 (5). - P. 502-509.
  • Dastani Z. et al. A novel nonsense apolipoprotein A-l mutation (apoA-l(E136X)) causes low HDL cholesterol in French Canadians // Atherosclerosis. - 2006. - Vol. 185 (1 ). - P. 127-136.
  • Wilhelm A.J. et al. Apo lipoprotein A I Modulates regulatory T cells in auto immune LDL r-/-, Apo A 1 -/mice // J Biol Chem. - 2010. - Vol. 285(46). - P. 16158.
  • Catapano A.L., Pirillo A., Bonacina F., Norata G.D. HDL in innate and adaptive immunity // Cardiovasc Res. - 2014. - Vol. 103 (3). - P. 372-383.
  • Tuteja S., Rader D.J. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm // Clin Pharmacol Ther. - 2014. - Vol. 96. - P. 48-56.
  • Di Angelantonio E., Sarwar N. Emerging Risk Factors. Collaboration Major lipids, apolipoproteins, and risk of vascular disease // JAMA. - 2009. - Vol. 302. - P. 1993-2000.
  • Mossuz P. et al. Apolipoprotein A I - a new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera // Proteomics Clin Appl. - 2007. - Vol. 1 (12). - P. 1605-1612.
  • Koldamova R.P. et al. Apolipoprotein A I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity // Biochemistry. - 2001. - Vol. 40 (12). - P. 3553-3560.
  • Rye K.A. et al. The metabolism and anti-atherogenic properties of HDL // J Lipid Res. - 2009. - Vol. 50. -S195-S200.
  • Camont L, Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease // Trends Mol Med. - 2011. - Vol. 17. - P. 594-603.
  • Gordon S.M. et al. High density lipoprotein: it's not just about lipid transport anymore // Trends Endocrinol Metab. - 2011,- Vol. 22. - P. 9-15.
  • Vanhamme L. et al. Apolipoprotein L-l is the trypanosome lytic factor of human serum // Nature. - 2003. -Vol. 422. - P. 83-87.
  • Singh I.P. et al. Lipoproteins account for part of the broad non-specific antiviral activity of human serum // Antiviral Res. 1 - 999. - Vol. 42 (3). - P. 211 -218.
  • Srinivas R.V. et al. Antiviral effects of Apolipoprotein AI and its synthetic amphipathic peptide analogs // Virology. - 1990.-Vol. 176 (1).-P. 48.
  • Neale T. HDL component an enemy to cancer in mice // Cardiology. - 2013. - P. 40579.
  • Ehmann M. et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling // Pancreas. - 2007. - Vol. 34. - P. 205-214.
  • Chong P.K. et al. Reduced plasma APOA1 level is associated with Gastric Tumor Growth in MKN45 mouse xenograft mode // J Proteomics. - 2010. - Vol. 73 (8). - P. 1632-1640.
  • Kozak K.R. et al. Characterization of serum biomarkers for detection of early stage ovarian cancer // Proteomics. - 2005. - Vol. 5. - P. 4589-4596.
  • Gillard B.K. et al. Apolipoproteins A-l, A-ll and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells // Biochim Biophys Acta. - 2009. - Vol. 1791. - P. 1125-1132.
  • Gao X. et al. Effect of apolipoprotein A-ll on the structure and stability of human high-density lipoprotein P. implications for the role of apoA-ll in HDL metabolism // Biochemistry. - 2012. - Vol. 51 (23). - P. 46334641.
  • Silva R.A. et al. The structure of apolipoprotein A-ll in discoidal high density lipoproteins // J Biol Chem. -2007. - Vol. 282 (13). - P. 9713-9121.
  • Maiga S.F., Kalopissis A.D., Chabert M. Apolipoprotein A-ll is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes // Biochimie. - 2014. - Vol. 96. - P. 56-66.
  • Green P.H. et al. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma // J Clin Invest. -1980. - Vol. 65. - P. 911-919.
  • Deng X. et al. The Structure of dimeric apolipoprotein A-IV and its mechanism of self-association // Structure. - 2012. - Vol. 20 (5). - P. 767-779.
  • Cui Y. et al. Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model // Am J Pathol. - 2011. - Vol. 178. - P.1298-1308.
  • Bergström J. et al. Two different types of amyloid deposits - apolipoprotein A-IV and transthyretin - in a patient with systemic amyloidosis // Lab Invest. - 2004. - Vol. 84 (8). - P. 981-988.
  • Nilsson S.K. et al. Apolipoprotein A-V: a potent triglyceride reducer // Atherosclerosis. - 2011. - Vol. 219 (1). - P.15-21.
  • Sharma V., Forte T.M., Ryan R.O. Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol // Curr Opin Lipidol. - 2013. - Vol. 24 (2). - P.153-159.
  • Mahley R.W., Weisgraber, K.H., and Huang, Y. Apolipoprotein E: Structure determines function - from atherosclerosis to Alzheimer's disease to AIDS // J. Lipid Res. - 2013. - Vol. 50. - S183-S188.
  • Getz, G.S., Reardon, C.A. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall // J. Lipid Res. - 2009. - Vol. 50. - S156-S161.
  • Davignon, J., Gregg R. E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis // Arteriosclerosis. - 1988. - Vol. 8, - P. 1-21.
  • Segrest J.P. et al. amphipathic helix in the exchangeable apolipoproteins. A review of secondary structure and function // J. Lipid Res. - 1999. - Vol. 33. - P. 141-166.
  • Mahley R.W., Ji S.Z. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E // J. Lipid. Res. - 1999. - Vol. 40. - P. 1-16.
  • Mahley R.W., Huang Y., Rail S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes//J. Lipid Res. - 1999. - Vol. 40. - P. 1933-1949.
  • Sundaram M., Yao Z. Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion // Arterioscler. Thromb. Vase. Biol. - 2012. - Vol. 32. - P. 1073-1078.
  • Huang Y. et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia // J. Biol. Chem. - 1998. - Vol. 273. - P. 26388-26393.
  • Weisgraber K.H., Innerarity T.L., Mahley R.W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site // J. Biol. Chem. - 1982. - Vol. 257. - P. 2518-2521.
  • Mahley R.W., Huang, Y., Rail S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes // J. Lipid Res. - 1999. - Vol. 40. - P. 1933-1949.
  • Dong L.M. et al. The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-Leiden: role in receptor-binding activity // J. Lipid Res. - Vol. 39. - P. 1173-1180.
  • Mann, W. A. et al. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia // J. Lipid Res. - 1995. - Vol. 36. - P. 517-525.
  • Saito H. et al. Effects of polymorphism on the lipid interaction of human apolipoprotein E // J. Biol. Chem. -2003. - Vol. 278. - P. 40723-40729.
  • Li H. et al. Molecular mechanisms responsible for the differential effects of ароЕЗ and apoE4 on plasma lipoprotein-cholesterol levels // Arterioscler. Thromb. Vase. Biol. - 2013. - Vol. 33. - P. 687-693.
  • Rensen P.C.N., Van Berkel T.J. C. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo // J. Biol. Chem. - 1996. - Vol. 271. -P. 14791-14799.
  • Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2 // Arterioscler Thromb Vase Biol. - 1999. - Vol. 19. - P. 472-484.
  • Weisgraber K.H., Mahley R.W., Kowal R.C. Apolipoprotein C-l modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta VLDL to low density lipoprotein receptor-related protein // J Biol Chem. - 1990. - Vol. 265. - P. 22453-22459.
  • Shachter N.S. Apolipoproteins C-l and C-III as important modulators of lipoprotein metabolism // Curr Opin Lipidol. - 2001. - Vol. 12. - P.297-304
  • Shachter N.S., Ebara T., Ramakrishnan R., Steiner G. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl // J Clin Invest. - 1996. - Vol. 98. - P.846-855
  • Bjorkegren J., Boquist S., Samnegard A. Accumulation of apolipoprotein C-l-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease // Circulation. - 2000. - Vol. 101. - P.227-230
  • Jackson C.L., Bruns G.A., Breslow J.L. Isolation and sequence of a human apolipoprotein Cll cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein Cll // Proc. Natl. Acad. Sci. USA. - 1984. - Vol. 81. - P. 2945-2949.
  • Nestel P. J., Fidge N. H. Apoprotein C metabolism in man // Adu. Lipid Res. 1982ю Vol. 19. P. 55-83.
  • LaRosa J.C. et al. A specific apoprotein activator for lipoprotein lipase // Biochem. Bwphys. Res. Commun. -1970.
  • Jong M.C., Hofker M.H., Havekes L.M. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2 // Arterioscler Thromb Vase Biol. - 1999. - Vol. 19. - P. 472-484.
  • Kostapanos M.S., Milionis H.J., Lagos K.G. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia // Eur J Pharmacol. - 2008. - Vol. 59. - P. 327-332.
  • Mabuchi H., Kamon N., Fujita H. Effects of Cs-514 on serumlipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia // Metabolism. - 1987. - Vol. 36. - P. 475-479.
  • Kostapanos M.S., Milionis H.J., Filippatos T.D. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia // Clin Ther. -2007. - Vol. 29. - P. 1403-1414.
  • Le N-A., Innis-Whitehouse W., Li X. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin // Metabolism. - 2000. - Vol. 49. - P. 167-177.
  • Kei A.A., Filippatos T.D., Tsimihodimos V. A review of the role of apolipoprotein C-ll in lipoprotein metabolism and cardiovascular disease // Metab Clin Exp. - 2012. - Vol. 61. - P. 906-921.
  • Lam C.W., Yuen Y.P., Cheng W.F. Missense mutation Leu72Pro located on the carboxyl terminal amphi-pathic helix of apolipoprotein C-ll causes familial chylomicronemia syndrome // Clinica Chimica Acta. -2006. - Vol. 364. - P. 256-259.
  • Okubo M., Toromanovic A., Ebara T. Apolipoprotein C-ll: a novel large deletion in APOC2 caused by AluAlu homologous recombination in an infant with apolipoprotein C-ll deficiency // Clinica Chimica Acta. -2015. - Vol. 438. - P. 148-153.
  • Ueda M., Dunbar R.L., Wolska A., A novel APOC2 missense mutation causing apolipoprotein C-ll deficiency with severe triglyceridemia and pancreatitis // J Clin Endocrinol Metab. - 2017. - Vol. 102. - P. 1454-1457.
  • Huynh K. Dual apoC-ll mimetic and apoC-lll antagonist for hypertriglyceridaemia // Nat Rev Cardiol. -2020.-Vol. 17 (4). - P.201.
  • Norata G.D., Tsimikas S., Pirillo A., Catapano A.L. Apolipoprotein C-IIIP. From Pathophysiology to Pharmacology // Trends Pharmacol Sci. -2015. - Vol. 36. - P. 675-687.
  • Wang C.S., McConathy W.J., Kloer H.U. Modulation of lipoproteinlipase activity by apolipoproteins. Effect of apolipoprotein C-lll // J Clin Invest. - 1985. - Vol. 75. - P. 384-390.
  • McConathy W.J., Gesquiere J.C., Bass H., Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-lll //J Lipid Res. - 1992. - Vol. 33. - P. 995-1003.
  • Kinnunen P.K.J., Ehnholm C. Effect of serum and C-apoproteins from very low-density lipoproteins on human postheparin plasma hepatienlipase. FEBS Lett. - 1976. - Vol. 65. - P. 354-357.
  • Quarfordt S.H., Michalopoulos G., Schirmer В. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat // J Biol Chem. - 1982. - Vol. 257. - P. 14642-14647.
  • Mann C.J., Troussard A.A., Yen F.T. Inhibitory effects of specific apolipoprotein C-lll isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor // J Biol Chem. - 1997. - Vol. 272. - P. 31348-31354.
  • Qin W., Sundaram M., Wang Y. Missense mutation in APOC3 within the C-terminal lipid binding domain of human Apo C-lll results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that Apo C-lll plays a major role in the formation of lipid precursors within the microsomal lumen // J Biol Chem. - 2011, - Vol. 286. - P. 27769-27780.
  • Chan D.C., Watts G.F., Nguyen M.N. Apolipoproteins C-lll and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics // Arterioscler Thromb Vase Biol. - 2006. - Vol. 26. -P. 590-596.
  • Taskinen M.R., Adiels M., Westerbacka J., Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects // Arterioscler Thromb Vase Biol. - 2011. - Vol. 31. - P. 2144-2150.
  • Cohn J.S., Patterson B.W., Uffelman K.D. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-lll is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity // J Clin Endocrinol Metab. -2004. - Vol. 89. - P. 3949-3855.
  • Mengdie L. et al. Apo CHI enrichment in HDL impairs HDL-mediated cholesterol efflux capacity // Sci Rep. -2017. - Vol. 7,- P. 2312.
  • Xu S. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake//J Lipid Res. - 1997. - Vol. 38. - P.1289-129.
  • Agnani G., Bard J.M., Candelier L. Interaction of LpB, LpBP.E, LpBP. C-lll, and LpBP.C-IIIP.E lipoproteins with the low density lipoprotein receptor of HeLa cells // Arterioscler Thromb. - 1991. - Vol. 11. - P. 1021 -1029.
  • Clavey V., Lestavel-Delattre S., Copin C. Modulation of lipoprotein В binding to the LDL receptor by exogenous lipids and apolipoproteins Cl, Cll, CHI, and E // Arterioscler Thromb Vase Biol. - 1995. - Vol. 15. - P. 963-971.
  • Vaisar T. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity // J Lipid Res. -2015. - Vol. 56. - P. 1519-1530.
  • Han C.Y. Serum amyloid A impairs the antiinflammatory properties of HDL // J Clin Invest. - 2016. - Vol. 126. - P. 266-281.
  • Kawakami A. Apolipoprotein CHI-induced THP-1 cell adhesion to endothelial cells involves pertussis toxinsensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation // Arterioscler Thromb Vase Biol. - 2007. - Vol. 27. - P. 219-225.
  • Le N.A., Ginsberg H.N. Independent regulation of plasma apolipoprotein-C-ll and apolipoprotein-C-lll concentrations in very low-density and high-density lipoproteins - implications for the regulation of the catabolism of these lipoproteins // J Lipid Res. - 1988. - Vol. 29. - P. 669-677.
  • Crosby J., Peloso G.M., Auer P.L., TG and HDL Working Group of the Exome Sequencing Project, National, Heart, Lung, and Blood Institute, Reiner AP, Boerwinkle E., Kathiresan S. Loss-of-function mutations in APOC3, triglycerides, and coronary disease // N Engl J Med. - 2014. - Vol. 371. - P. 22-31.
  • Jorgensen A.B., Frikke-Schmidt R., Nordestgaard B.G., Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. - 2014. - Vol. 371. - P. 32-41.
  • Jensen M.K., Rimm E.B., Furtado J.D., Sacks F.M. Apolipoprotein C-lll as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease // J Am Heart Assoc. - 2012. -Vol. 1. - P. jah3-e000232.
  • Riwanto M. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling // Circulation. - 2013. - Vol. 127. - P.891 -904.
  • Investigators O.T. Omega-3 fatty acids and cardiovascular outcomes in patients with dysglycemia // N Engl J Med. - 2012. - Vol. 367. - P. 309-318.
  • Chang P.Y. Identification of the HDL- ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general populationP. the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan // Lipids Health Dis. - 2012. - Vol. 11. - P. 162.
  • Xiong X. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it // Lipids Health Dis. - 2015. - Vol. 14. - P. 127.
  • Norata G.D., Tsimikas S., Pirillo A., Catapano A.L. Apolipoprotein C-IIIP. From Pathophysiology to Pharmacology. Trends Pharmacol Sci. - 2015. - Vol. 36. - P. 675-687.
  • Graham M.J., Lee R.G., Bell T.A., Antisense oligonucleotide inhibition of apolipoprotein C-lll reduces plasma triglycerides in rodents, nonhuman primates, and humans // Circ Res. - 2013. - Vol. 112. - P. 14791490.
  • Diffenderfer M.R., Schaefer E.J. The composition and metabolism of large and small LDL // Curr Opin Lipidol. - 2014. - Vol. 25. - P. 221-226.
  • Jialal I. A practical approach to the laboratory diagnosis of dyslipidemia // Am. J. Clin. Pathol. - 1996. -Vol. 106 (1). - P. 128-138.
  • Contois J.H. et al. AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Apolipoprotein В and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices // Clin. Chem. - 2009. - Vol. 55 (3). - P.407-419.
  • Wilson P.W.F. et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol P. A Report of the American College of Cardiology /American Heart Association Task Force on Clinical Practice Guidelines // Circulation. - 2019. - Vol. 139 (25). - P. e1144-e1161.
  • Devaraj S., Jialal I. Biochemistry, Apolipoprotein B. // StatPearls. StatPearls Publishing, Treasure Island (FL). 2019.
  • Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia // Atherosclerosis. - 1993. - Vol. 104. - P. 1-18.
  • Jialal I., Barton D.P. Diagnosis of Familial Hypercholesterolemia // Am. J. Clin. Pathol. -2016. - Vol. 145 (4). - P.437-439.
  • Berman A.N., Blankstein R. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: Focus on Risk Assessment and Therapeutic Options // Curr Cardiol Rep. - 2019. - Vol. 21 (9). - P.110.
  • Dubé J.B., Botta M.B., Hegele R.A. Lipoprotein(a): more interesting than ever after 50 years // Curr Opin Lipidol. - 2012. - Vol. 23 (2). - P. 133-140.
  • Boerwinkle E. et al. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein) concentrations // J. Clin. Invest. - 1992. - Vol. 90. - P. 52-60.
  • Kraft H.G. et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is nonrandom // Eur. J. Hum. Genet. - 1996. - Vol. 4. - P. 74-87.
  • Kraft H.G. et al. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration // Hum. Genet. - 1992. - Vol. 90. - P. 220-230.
  • Lackner C. et al. Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis // J. Clin. Invest. - 1991. - Vol. 87. - P. 2153-2161.
  • Schmidt K., Noureen A., Kronenberg F., Utermann G. Structure, function, and genetics of lipoprotein (a) // J. Lipid Res. - 2016. - Vol. 57. - P. 1339-1359.
  • Leibundgut G. et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a) // J Lipid Res. - 2013. - Vol. 54 (10). - P. 2815-2830.
  • Miles L.A. et al. Interaction of Lp(a) with plasminogen binding sites on cells // Thromb Haemost. - 1995. -Vol. 73. - P. 458-465.
  • Sotiriou S.N. et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with mac-1 integrin // FASEB J. - 2006. - Vol. 20. - P. 559-561.
  • Jacobson T.A. Lipoprotein(a). Cardiovascular Disease, and Contemporary Management // Mayo Clin Proc. -2013. - Vol. 88 (11 ). - P. 1294-1311.
  • Lippi G., Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor // Crit Rev Clin Lab Sci. - 2003. -Vol. 40. - P. 1-42.
  • Becker L. et al. A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp (a) formation // J Biol Chem. - 2003. - Vol. 278 (16). - P. 14074-14081.
  • Ho-Tin-Noe B. et al. Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis // FEBS J. - 2005. - Vol. 272. - P. 3387-3400.
  • Romagnuolo R. et al. Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a) // J Lipid Res. - 2014. - Vol. 55 (4). - P. 625-634.
  • Kang C. et al. Lipoprotein(a) isoforms display differences in affinity for plasminogen-like binding to human mononuclear cells // Arterioscler Thromb Vase Biol. - 1997. - Vol. 17. - P. 2036-2043.
  • Gabel B.R. et al. Lipoprotein(a) assembly. Quantitative assessment of the role of apo(a) kringle IV types 210 in particle formation // Arterioscler Thromb Vase Biol. - 1996. - Vol. 16. - P. 1559-1567.
  • Willeit P., Kiechl S., Kronenberg F. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study // J Am Coll Cardiol. - 2014. - Vol. 64 (9). -P. 851-860.
  • Sechi L.A., Kronenberg F., De Carli S. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension // JAMA. - 1997. - Vol. 277. - P. 1689.
  • Kassner U., Schlabs T., Rosada A. Lipoprotein(a)-An independent causal risk factor for cardiovascular disease and current therapeutic options // Atheroscler Suppl. - 2015. - Vol. 18. - P. 263-267.
  • Erqou S., Kaptoge S., Perry P.L. Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality // JAMA. - 2009. - Vol. 302( 4). - P. 412-423.
  • Yeang C., Witztum J.L., Tsimikas S. 'LDL-C = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering // Curr Opin Lipidol. - 2015. - Vol. 26 (3). - Vol. 169-178.
  • Van van Wissen S., Smilde T.J., Trip M.D. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia // Heart. - 2003. - Vol. 89. -P. 893-896.
  • Borresen A.L., Berg K., Dahlén G. The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity // (SRCBC) Artery. - 1981. - Vol. 9. - P. 77.
  • Nordestgaard B.G., Chapman M.J., Ray K. Lipoprotein(a) as a cardiovascular risk factor: current status // Eur Heart J. - 2010. - Vol. 31 (23). - P. 2844-2853.
  • Graham M.J., Viney N., Crooke R. Antisense Inhibition of Apolipoprotein(a) to Lower Plasma Lipoprotein(a) Levels in Humans // J Lipid Res. - 2015. - pii: jlr. R052258.
  • Tsimikas S., Viney N.J., Hughes S.G. Antisense therapy targeting apolipoprotein(a): a randomised, doubleblind, placebo-controlled phase 1 study // Lancet. - 2015. - Vol. 386 (10002). - P. 1472-1483.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp